0000000001060779

AUTHOR

Smith D

showing 2 related works from this author

Measurement of triple gauge WWγ couplings at LEP2 using photonic events

1998

A study of events with photons and missing energy has been performed with the data sample obtained with the ALEPH detector at centre-of-mass energies from 161 to 184 GeV,corresponding to a total integrated luminosity of about 80 pb**-1.The measured distributions are in agreement with Standard Model predictions, leading to constraints on W W gamma gauge coupling parameters Delta(kappa_gamma) and lambda_gamma. The results from the fit to the cross sectionsand to the energy and angular distributions of the photons are: Delta(kappa_gamma) = 0.05 +1.15/-1.10 (stat) +/- 0.25 (syst) lambda_gamma = 0.05 +1.55/-1.45 (stat) +/- 0.30 (syst) A study of events with photons and missing energy has been pe…

PhysicsNuclear and High Energy PhysicsParticle physicsMissing energyPhotonLuminosity (scattering theory)Astrophysics::High Energy Astrophysical PhenomenaElectron–positron annihilationLEPGauge (firearms)LambdaStandard ModelALEPH Experimenttriple gauge WWgammaNuclear physicsALEPH Experiment; LEP; triple gauge WWgammaHigh Energy Physics::ExperimentAstrophysics::Earth and Planetary AstrophysicsNuclear ExperimentALEPH experimentParticle Physics - ExperimentPhysics Letters B
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct